BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $11

Moomoo News14:34 ET

J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $10

Moomoo News14:34 ET

Adaptive Biotechnologies Is Maintained at Buy by Goldman Sachs

Dow Jones12:56 ET

Adaptive Biotechnologies Price Target Raised to $10.00/Share From $9.00 by Goldman Sachs

Dow Jones12:56 ET

Adaptive Biotechnologies Analyst Ratings

Benzinga12:47 ET

William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating

Moomoo NewsMay 2 07:31 ET

TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $13

Moomoo NewsMay 2 07:31 ET

Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsMay 2 07:31 ET

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Adaptive Biotechnologies (ADPT)

TipRanksMay 2 07:03 ET

Positive Outlook for Adaptive Biotechnologies: Strong Revenue Growth and Strategic Initiatives Support Buy Rating

TipRanksMay 2 06:54 ET

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), CVS Health (CVS) and Cytokinetics (CYTK)

TipRanksMay 2 06:27 ET

BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsApr 28 07:31 ET

BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsApr 9 07:31 ET

TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsMar 31 07:31 ET

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Adaptive Biotechnologies (ADPT) and Alnylam Pharma (ALNY)

TipRanksMar 31 06:56 ET

Goldman Sachs Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsMar 24 07:31 ET

Adaptive Biotechnologies Analyst Ratings

BenzingaMar 21 10:01 ET

Goldman Sachs Upgrades Adaptive Biotechnologies(ADPT.US) to Buy Rating, Raises Target Price to $9

Moomoo NewsMar 21 07:33 ET

Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8

MT NewswiresMar 21 07:16 ET

BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsMar 18 07:32 ET